<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/" >

<channel>
	<title>Research in 2018 | ARSACS</title>
	<atom:link href="https://arsacs.com/fr/category/research-2018/feed/" rel="self" type="application/rss+xml" />
	<link>https://arsacs.com/fr</link>
	<description>Research That Heals</description>
	<lastBuildDate>Mon, 16 Mar 2026 22:10:20 +0000</lastBuildDate>
	<language>fr-CA</language>
	<sy:updateperiod>
	hourly	</sy:updateperiod>
	<sy:updatefrequency>
	1	</sy:updatefrequency>
	

<image>
	<url>https://arsacs.com/wp-content/uploads/2021/02/cropped-FAVICON-32x32.png</url>
	<title>Research in 2018 | ARSACS</title>
	<link>https://arsacs.com/fr</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Integrated Validation Pipeline for Candidate Drugs for ARSACS- Dr. Bernard Brais</title>
		<link>https://arsacs.com/fr/integrated-validation-pipeline-for-candidate-drugs-for-arsacs-dr-bernard-brais-2/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Thu, 23 Aug 2018 20:12:31 +0000</pubDate>
				<category><![CDATA[Research in 2018]]></category>
		<guid ispermalink="false">https://clone.arsacs.com/integrated-validation-pipeline-for-candidate-drugs-for-arsacs-dr-bernard-brais/</guid>

					<description><![CDATA[The aims of the project are to validate candidate compounds in neurons and to combine genomics and proteomics strategies to pinpoint pathways affected by candidate drugs. Duration: One year Grant : $80,000 Contact Dr. Bernard Brais, co-director of the neuromuscular group of the Montreal Neurological Institute and Hospital 3801 University Street Montreal, Quebec, Canada H3A [...]]]></description>
										<content:encoded><![CDATA[The aims of the project are to validate candidate compounds in neurons and to combine genomics and proteomics strategies to pinpoint pathways affected by candidate drugs.

Duration: One year
Grant :  $80,000

Contact

<div id="attachment_192" style="width: 160px" class="wp-caption alignleft"><img decoding="async" aria-describedby="caption-attachment-192" src="https://arsacs.com/wp-content/uploads/2021/02/Brais_2015-150x150-2.jpg" alt="Dr. Bernard Brais" width="150" height="150" class="size-thumbnail wp-image-192"><p id="caption-attachment-192" class="wp-caption-text">Dr. Bernard Brais</p></div>

Dr. Bernard Brais, co-director of the neuromuscular group of the Montreal Neurological Institute and Hospital
3801 University Street Montreal, Quebec, Canada H3A 2B4
Tel:(514)-398-3334; Email: bernard.brais@mcgill.ca]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Elucidating Mechanisms Underlying Motor Coordination Rescue in a Mouse Model of ARSACS- Dr. Alanna Watt and Dr. Anne McKinney</title>
		<link>https://arsacs.com/fr/elucidating-mechanisms-underlying-motor-coordination-rescue-in-a-mouse-model-of-arsacs-dr-alanna-watt-and-dr-anne-mckinney-2-2/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Fri, 27 Jul 2018 21:52:59 +0000</pubDate>
				<category><![CDATA[Research in 2018]]></category>
		<guid ispermalink="false">https://clone.arsacs.com/elucidating-mechanisms-underlying-motor-coordination-rescue-in-a-mouse-model-of-arsacs-dr-alanna-watt-and-dr-anne-mckinney-2/</guid>

					<description><![CDATA[Description Aim 1 Elucidate mechanism underlying MitoQ rescue of motor coordination in Sacs-/- mice: (i)test mitochondrial dynamics and morphology using Mito-tracker administered intracellularly in Purkinje cells in treated and untreated Sacs−/− mice, (ii) test mitochondrial function using assays for mitochondrial respiration and energy consumption, and (iii) determine whether MitoQ rescues the abnormal somatodendritic localization of [...]]]></description>
										<content:encoded><![CDATA[Description
Aim 1 Elucidate mechanism underlying MitoQ rescue of motor coordination in Sacs-/- mice:
(i)test mitochondrial dynamics and morphology using Mito-tracker administered intracellularly in Purkinje cells in treated and untreated Sacs−/− mice, (ii) test mitochondrial function using assays for mitochondrial respiration and energy consumption, and (iii) determine whether MitoQ rescues the abnormal somatodendritic localization of phosphorylated neurofilament in Sacs−/− mice.In addition to understanding the mechanism by which MitoQ rescues motor behaviour, the work will continue with the Brais lab to understand how and if a drug recently identified by a drug screen they conducted with V151 improves Purkinje cell morphological and physiological deficits.

Aim 2 Identify mechanism(s) underlying Purkinje cell firing deficits in Sacs-/- mice.
Over the coming 2018/2019 year we expect to make substantial advances in understanding the following 5 questions:
(a) How does MitoQ lead to behavioral improvements in Sacs−/− mice?
(b) Does V151 rescue physiological abnormalities in Sacs−/− mice?
(c) Are glutamate transporters altered in Sacs−/− mouse cerebellum?
(d) Does rescue of firing rate directly ameliorate behavioral phenotype in Sacs−/− mice?
(e) Is zebrin neuroprotective in Sacs−/− mouse cerebellum?

Duration : One year
Grant: $125,000
Contacts:

<div id="attachment_132" style="width: 160px" class="wp-caption alignleft"><img loading="lazy" decoding="async" aria-describedby="caption-attachment-132" src="https://arsacs.com/wp-content/uploads/2021/02/watt-1-150x150-2.jpg" alt="Dre Alanna Watt" width="150" height="150" class="size-thumbnail wp-image-132"><p id="caption-attachment-132" class="wp-caption-text">Dre Alanna Watt</p></div>

Dr. Alanna Watt, Department of Biology McGill University Bellini Life Sciences Bldg.
3469 Sir William Osler, Montreal, Quebec Canada H3G 0B1 Office: Rm. 265 | Lab: Rm. 257
Tel: (514)-398-2806; Fax: (514)-398-5069; Email: alanna.watt@mcgill.ca

<div id="attachment_186" style="width: 160px" class="wp-caption alignleft"><img loading="lazy" decoding="async" aria-describedby="caption-attachment-186" src="https://arsacs.com/wp-content/uploads/2021/02/Anne-McKinney-150x150-2.jpg" alt="Dr Anne McKinney" width="150" height="150" class="size-thumbnail wp-image-186"><p id="caption-attachment-186" class="wp-caption-text">Dr Anne McKinney</p></div>

Dr. Anne McKinney, Department of Pharmacology and Therapeutics, McGill University Bellini Life Sciences Bldg
3469 Sir William Osler, Montreal, Quebec Canada H3G 0B1
Tel: (514)-398-5685; Fax: (514)-398-2045; Email: anne.mckinney@mcgill.ca]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Phenotyping ARSACS in Vitro Using hiPSCs Reprogrammed from Patients and Differentiated into Motor Neurons and Schwabb cells &#8211; Dr. François Berthod</title>
		<link>https://arsacs.com/fr/phenotyping-arsacs-in-vitro-using-hipscs-reprogrammed-from-patients-and-differentiated-into-motor-neurons-and-schwabb-cells-dr-francois-berthod-2/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Fri, 27 Jul 2018 21:52:13 +0000</pubDate>
				<category><![CDATA[Research in 2018]]></category>
		<guid ispermalink="false">https://clone.arsacs.com/phenotyping-arsacs-in-vitro-using-hipscs-reprogrammed-from-patients-and-differentiated-into-motor-neurons-and-schwabb-cells-dr-francois-berthod/</guid>

					<description><![CDATA[The objectives are to: (1) develop and characterize a 3D in vitro human model constituted of fibroblasts, motor neurons, Schwann cells and myoblasts that recapitulate the ARSACS phenotype at the motor neuron scale, (2) determine whether the ARSACS phenotype is homogeneous between different patients in vitro. Duration: one year Grant: $80,000 contact: Dr. François Berthod, [...]]]></description>
										<content:encoded><![CDATA[The objectives are to: (1) develop and characterize a 3D in vitro human model constituted of fibroblasts, motor
neurons, Schwann cells and myoblasts that recapitulate the ARSACS phenotype at the motor neuron scale, (2)
determine whether the ARSACS phenotype is homogeneous between different patients in vitro.

Duration: one year
Grant: $80,000

<img loading="lazy" decoding="async" src="https://arsacs.com/wp-content/uploads/2021/02/Francois_Berthod-2.jpg" alt="" width="128" height="128" class="alignleft size-full wp-image-3566">

contact:
Dr. François Berthod, professor department of Surgery
Faculty of medicine of University Laval
tel: 418-990-8255 x61705; courriel: francois.berthod@fmed.ulaval.ca]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Unbiased Sacsin Client Identification and Genetic Intervention in a Mouse Model of ARSACS- Dr. Stephen Strack</title>
		<link>https://arsacs.com/fr/unbiased-sacsin-client-identification-and-genetic-intervention-in-a-mouse-model-of-arsacs-dr-stephen-strack-2/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Fri, 27 Jul 2018 21:51:37 +0000</pubDate>
				<category><![CDATA[Research in 2018]]></category>
		<guid ispermalink="false">https://clone.arsacs.com/unbiased-sacsin-client-identification-and-genetic-intervention-in-a-mouse-model-of-arsacs-dr-stephen-strack/</guid>

					<description><![CDATA[This research project utilizes Sacs KO mice to answer two fundamental questions: 1) Can we leverage recent advances in quantitative proteomics to uncover early biomarkers and perhaps drivers of ARSACS pathology in the cerebellum? 2) Can genetic modulation of the mitochondrial fission/fusion equilibrium counteract cerebellar symptoms and PC degeneration? Results from this research are expected [...]]]></description>
										<content:encoded><![CDATA[This research project utilizes Sacs KO mice to answer two fundamental questions:
1) Can we leverage recent advances in quantitative proteomics to uncover early biomarkers and perhaps drivers of ARSACS pathology in the cerebellum?
2) Can genetic modulation of the mitochondrial fission/fusion equilibrium counteract cerebellar symptoms and PC degeneration? Results from this research are expected to advance our understanding of ARSACS disease mechanisms and point to avenues for therapeutic intervention.

Duration: one year
Grant: $50,000

Contact :

<div id="attachment_228" style="width: 160px" class="wp-caption alignleft"><img loading="lazy" decoding="async" aria-describedby="caption-attachment-228" src="https://arsacs.com/wp-content/uploads/2021/02/DrStefanStrack-150x150-2.jpg" alt="Dr Stefan Strack" width="150" height="150" class="size-thumbnail wp-image-228"><p id="caption-attachment-228" class="wp-caption-text">Dr Stefan Strack</p></div>

Dr.Stefan Strack, Professor of Pharmacology University of Iowa Carver College of Medicine
2-452 BSB, 51 Newton Rd. Iowa City, IA 52242
Tel:(office/lab): (319)384-44[39/47]; Fax: (319) 335-8930
www.medicine.uiowa.edu/pharmacology/faculty/strack.html]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Exploring Neuronal Roles for Sacsin: from Dendritic Spines to Neuronal Polarity- Dr. Bernard Brais</title>
		<link>https://arsacs.com/fr/exploring-neuronal-roles-for-sacsin-from-dendritic-spines-to-neuronal-polarity-dr-bernard-brais-2/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Fri, 27 Jul 2018 21:50:22 +0000</pubDate>
				<category><![CDATA[Research in 2018]]></category>
		<guid ispermalink="false">https://clone.arsacs.com/exploring-neuronal-roles-for-sacsin-from-dendritic-spines-to-neuronal-polarity-dr-bernard-brais/</guid>

					<description><![CDATA[The focus will be on Aim 1. The objective is to submit a paper that will elucidate the role of Sacsin and EndoB2 in dendritic spines that will include our BioID results. Aim 2. We will explore if a neuronal polarity defect in cytoskeletal protein trafficking might also be an important aspect of ARSACS pathophysiology. [...]]]></description>
										<content:encoded><![CDATA[The focus will be on

Aim 1. The objective is to submit a paper that will elucidate the role of Sacsin and EndoB2 in dendritic spines that will include our BioID results.

Aim 2.  We will explore  if a neuronal polarity defect in cytoskeletal protein trafficking might also be an important aspect of
ARSACS pathophysiology.

Duration: One year
Grant $80,000

Contact

<div id="attachment_192-2" style="width: 160px" class="wp-caption alignleft"><img loading="lazy" decoding="async" aria-describedby="caption-attachment-192-2" src="https://arsacs.com/wp-content/uploads/2021/02/Brais_2015-150x150-2.jpg" alt="Dr. Bernard Brais" width="150" height="150" class="size-thumbnail wp-image-192"><p id="caption-attachment-192-2" class="wp-caption-text">Dr. Bernard Brais</p></div>

Dr. Bernard Brais, co-director of the neuromuscular group of the Montreal Neurological Institute and Hospital
3801 University Street Montreal, Quebec, Canada H3A 2B4
Tel:(514)-398-3334; Email: bernard.brais@mcgill.ca]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Unravelling Progression Biomarkers in ARSACS: a Multicenter, Transmodal Combined Fluid Biomarker and Magnetic Resonance Imaging Study &#8211; Dr. Matthis Synofzik and Dr. Roberta La Piana</title>
		<link>https://arsacs.com/fr/unravelling-progression-biomarkers-in-arsacs-a-multicenter-transmodal-combined-fluid-biomarker-and-magnetic-resonance-imaging-study-dr-matthis-synofzik-and-dr-roberta-la-piana-2/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Fri, 27 Jul 2018 21:49:46 +0000</pubDate>
				<category><![CDATA[Research in 2018]]></category>
		<guid ispermalink="false">https://clone.arsacs.com/unravelling-progression-biomarkers-in-arsacs-a-multicenter-transmodal-combined-fluid-biomarker-and-magnetic-resonance-imaging-study-dr-matthis-synofzik-and-dr-roberta-la-piana/</guid>

					<description><![CDATA[A combined transmodal fluid biomarker and neuroimaging study to unravel progression biomarkers for ARSACS, bringing together a unique transatlantic, multi-center consortium which will yield the by far largest , most comprehensive biomarker investigation in ARSACS worlwide, creating combined clinical, biomaterialand multimodal MRI data-sets from 125 ARSACS patients across continents. Fluid biomarker investigations will focus on [...]]]></description>
										<content:encoded><![CDATA[A combined transmodal fluid biomarker and neuroimaging study to unravel progression biomarkers for ARSACS, bringing together a unique transatlantic, multi-center consortium which will yield the by far largest , most comprehensive biomarker investigation in ARSACS worlwide, creating combined clinical, biomaterialand multimodal MRI data-sets from 125 ARSACS patients across continents. Fluid biomarker investigations will focus on neurofilaments (NFs), a particularly promissing blood biomarker candidate in ARSACS.

Duration: on year
Grant: $90,000 per year
Contacts:

<img loading="lazy" decoding="async" src="https://arsacs.com/wp-content/uploads/2021/02/Matthis_Synofzik-2.jpg" alt="" width="128" height="128" class="alignleft size-full wp-image-3544">

Dr Matthis Synofzik, Dept. of Neurodegenerative Diseases Hertie-Institute for Clinical Brain Research
Hoppe-Seyler-Strasse 3 72076 Tübingen, Germany
Tel: 49(0)7071-2982060; Fax: 49 (0)7071-2925001; email: matthis.synofzik@uni-tuebingen.de

<img loading="lazy" decoding="async" src="https://arsacs.com/wp-content/uploads/2021/02/Roberta_La_Piana-2.jpg" alt="" width="128" height="128" class="alignleft size-full wp-image-3543">
Dr Roberta La Piana , Montreal Neurological Institute, McGill University
Montreal, Quebec
email:  roberta.lapiana@mail.mcgill.ca]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Unravelling Co-Translational Quality Control of Mutant Sacsin in the ARSACS Pathogenesis &#8211; Dr. Francesca Maltecca</title>
		<link>https://arsacs.com/fr/unravelling-co-translational-quality-control-of-mutant-sacsin-in-the-arsacs-pathogenesis-dr-francesca-maltecca-2/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Fri, 27 Jul 2018 21:48:45 +0000</pubDate>
				<category><![CDATA[Research in 2018]]></category>
		<guid ispermalink="false">https://clone.arsacs.com/unravelling-co-translational-quality-control-of-mutant-sacsin-in-the-arsacs-pathogenesis-dr-francesca-maltecca/</guid>

					<description><![CDATA[The main objectives of this research project are to: (i) verify if a co-translational QC is the cause of sacsin absence in patients, thus uncovering the earliest step in ARSACS pathogenesis; (ii) ameliorate genotype-phenotype correlation in ARSACS by assaying residual amount of sacsin levels in a panel of patient fibroblasts carrying different mutations. The comprehension [...]]]></description>
										<content:encoded><![CDATA[The main objectives of this research project are to:
(i) verify if a co-translational QC is the cause of sacsin absence in patients, thus uncovering the
earliest step in ARSACS pathogenesis;
(ii) ameliorate genotype-phenotype correlation in ARSACS by assaying residual amount of sacsin
levels in a panel of patient fibroblasts carrying different mutations.
The comprehension of the molecular mechanism underlying loss of mutant sacsin is crucial to
improve the knowledge on ARSACS pathogenesis.

Duration: One year
Grant : $40,000

Contact:

<div id="attachment_234" style="width: 160px" class="wp-caption alignleft"><img loading="lazy" decoding="async" aria-describedby="caption-attachment-234" src="https://arsacs.com/wp-content/uploads/2021/02/DrFrancescaMaltecca-150x150-2.jpg" alt="Dre Francesca Maltecca" width="150" height="150" class="size-thumbnail wp-image-234"><p id="caption-attachment-234" class="wp-caption-text">Dre Francesca Maltecca</p></div>

Dr. Francesca Maltecca, Universita Vita-Salute San Raffaele
Via Olgettina 60 20132 Milan, Italy
Tel:39 022643.9116; Fax: 39 022643.6352 ; Email: maltecca.francesca@hsr.it]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Caractérisation du profil clinique de la clientèle pédiatrique atteinte de l’ARSACS- Dre Cynthia Gagnon</title>
		<link>https://arsacs.com/fr/caracterisation-du-profil-clinique-de-la-clientele-pediatrique-atteinte-de-larsacs-dre-cynthia-gagnon-2/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Fri, 27 Jul 2018 21:47:36 +0000</pubDate>
				<category><![CDATA[Research in 2018]]></category>
		<guid ispermalink="false">https://clone.arsacs.com/caracterisation-du-profil-clinique-de-la-clientele-pediatrique-atteinte-de-larsacs-dre-cynthia-gagnon/</guid>

					<description><![CDATA[Les objectifs de ce projet sont de : 1. Documenter les atteintes motrices des membres inférieurs et supérieurs des enfants atteints d’ARSACS en termes de coordination, endurance et vitesse de marche, force des mains et sévérité de la maladie; 2. Déterminer la validité de construit des outils pour la clientèle pédiatrique atteinte d’ARSACS. Méthode Devis [...]]]></description>
										<content:encoded><![CDATA[Les objectifs de ce projet sont de :
1. Documenter les atteintes motrices des membres inférieurs et supérieurs des enfants atteints
d’ARSACS en termes de coordination, endurance et vitesse de marche, force des mains et
sévérité de la maladie;
2. Déterminer la validité de construit des outils pour la clientèle pédiatrique atteinte d’ARSACS.
Méthode
Devis : Transversal multicentrique
Participants : Le recrutement se fera au sein des cohortes de patients suivis à la clinique des maladies
neuromusculaires de Saguenay, à l’Institut de réadaptation en déficience physique de Québec (IRDPQ)
et au centre de réadaptation Marie-Enfant de Montréal.

Duration: one year

Grant: $23,500

Contact:

<div id="attachment_128" style="width: 160px" class="wp-caption alignleft"><img loading="lazy" decoding="async" aria-describedby="caption-attachment-128" src="https://arsacs.com/wp-content/uploads/2021/02/gagnon-1-150x150-2.jpg" alt="Cynthia Gagnon" width="150" height="150" class="size-thumbnail wp-image-128"><p id="caption-attachment-128" class="wp-caption-text">Cynthia Gagnon</p></div>

Dre Cynthia Gagnon
1200 Jonquière, QC G7X 7X2
TEL: 1-418-695-7700 poste 2756; Fax: 1-418-695-7758; email: Cynthia.Gagnon4@USherbrooke.ca]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Development of Optimized Molecules That Reverse The Molecular Phenotype of ARSACS &#8211; Dr. Michel Bouvier</title>
		<link>https://arsacs.com/fr/development-of-optimized-molecules-that-reverse-the-molecular-phenotype-of-arsacs-dr-michel-bouvier-2/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Fri, 27 Jul 2018 21:46:58 +0000</pubDate>
				<category><![CDATA[Research in 2018]]></category>
		<guid ispermalink="false">https://clone.arsacs.com/development-of-optimized-molecules-that-reverse-the-molecular-phenotype-of-arsacs-dr-michel-bouvier/</guid>

					<description><![CDATA[The goal of this project is to develop small molecules that reverse the cellular phenotype of ARSACS into a drug that would stop the progression of the disease and/or lead to clinical improvement. The project is a multidisciplinary collaboration between Dr Bernard Brais’ (McGill Univ.) and Dr Michel Bouvier’s (IRIC, Institute of Researcher in Immunology [...]]]></description>
										<content:encoded><![CDATA[The goal of this project is to develop small molecules that reverse the cellular phenotype of ARSACS into
a drug that would stop the progression of the disease and/or lead to clinical improvement. The project is
a multidisciplinary collaboration between Dr Bernard Brais’ (McGill Univ.) and Dr Michel Bouvier’s (IRIC,
Institute of Researcher in Immunology and Cancer, Univ. of Montreal) laboratories with the participation
of the High Throughput Screening (HTS) and Medicinal Chemistry core facilities at IRIC.

Duration: One year
Grant: $150,000

Contact

<img loading="lazy" decoding="async" src="https://arsacs.com/wp-content/uploads/2021/02/Michel_Bouvier-1-150x150-2.jpg" alt="" width="150" height="150" class="alignleft size-thumbnail wp-image-3353">

Dr.Michel Bouvier, Institute for Research in Immunology and Cancer  (IRIC)
IRIC | Université de Montréal C.P. 6128, succursale Centre-ville, Montréal (Québec) H3C 3J7
Tel: (514)-343-6319 ; Email: michel.bouvier@umontreal.ca]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Functional and Structural Studies of Sacsin Using Baculovirus Expression Systems- Dr. Kalle Gehring</title>
		<link>https://arsacs.com/fr/functional-and-structural-studies-of-sacsin-using-baculovirus-expression-systems-dr-kalle-gehring-2/</link>
		
		<dc:creator><![CDATA[ARSACS]]></dc:creator>
		<pubDate>Fri, 27 Jul 2018 21:46:19 +0000</pubDate>
				<category><![CDATA[Research in 2018]]></category>
		<guid ispermalink="false">https://clone.arsacs.com/functional-and-structural-studies-of-sacsin-using-baculovirus-expression-systems-dr-kalle-gehring/</guid>

					<description><![CDATA[The central goal is to obtain pure full-length sacsin in high enough concentration for structural and functional assays. We also aim to express and study the interaction of large multidomain fragments of sacsin. These will allow us to study the structure of sacsin by X-ray crystallography and cryo-electron microscopy. Purified protein will also enable assays [...]]]></description>
										<content:encoded><![CDATA[The central goal is to obtain pure full-length sacsin in high enough concentration for
structural and functional assays. We also aim to express and study the interaction of large
multidomain fragments of sacsin. These will allow us to study the structure of sacsin by X-ray
crystallography and cryo-electron microscopy. Purified protein will also enable assays of sacsin
chaperone function and protein-protein interactions.

Duration: one year
Grant: $80,000

Contact:
<img loading="lazy" decoding="async" src="https://arsacs.com/wp-content/uploads/2021/02/DrKalleGehring-150x150-3.jpg" alt="" width="150" height="150" class="alignleft size-full wp-image-3569">

Dr.Kalle Gehring Dept. of Biochemistry, McGill University
Life Science Complex, Room 469, 3649 Prom. Sir William Osler,Montreal QC, H3G 0B1
Tel: 514-398-7287; Email:kalle.gehring@mcgill.ca]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>